Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55

RB Rothman, JL Cadet, HC Akunne, ML Silverthorn, MH Baumann, FI Carroll, KC Rice, BR de Costa, JS Partilla and JB Wang

Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse/NIH Addiction Research Center, Baltimore, Maryland.

The drug 3 beta-[4'-iodophenyl]tropan-2 beta-carboxylic acid methyl ester (RTI-55) is a cocaine congener with high affinity for the dopamine transporter (Kd < 1 nM). The present study characterized [125I]RTI-55 binding to membranes prepared from rat, monkey and human caudates and COS cells transiently expressing the cloned rat dopamine (DA) transporter. Using the method of binding surface analysis, two binding sites were resolved in rat caudate: a high-capacity binding site (site 1, Bmax = 11,900 fmol/mg of protein) and a low-capacity site (site 2, Bmax = 846 fmol/mg of protein). The Kd (or Ki) values of selected drugs at the two sites were as follows: (Ki for high-capacity site and Ki for low-capacity site, respectively): RTI-55 (0.76 and 0.21 nM), 1-[2-diphenyl-methoxy)ethyl]-4-(3-phenylpropyl)piperazine (0.79 and 358 nM), mazindol (37.6 and 631 nM), 2 beta-carbomethoxy-3 beta-(4- fluorophenyl)tropane (45.0 and 540 nM) and cocaine (341 and 129 nM). Nisoxetine, a selective noradrenergic uptake blocker, had low affinity for both sites. Serotonergic uptake blockers had a high degree of selectivity and high affinity for the low-capacity binding site (Ki of citalopram = 0.38 nM; Ki of paroxetine = 0.033 nM). The i.c.v. administration of 5,7-dihydroxytryptamine to rats pretreated with nomifensine (to protect dopaminergic and noradrenergic nerve terminals) selectively decreased the Bmax of site 2, strongly supporting the idea that site 2 is a binding site on the serotonin (5-HT) transporter. This serotonergic lesion also increased the affinity of [125I]RTI-55 for the DA transporter by 10-fold. The ligand selectivity of the caudate 5-HT transporter was different from the [I125]RTI-55 binding site on the 5- HT transporter present in membranes prepared from whole rat brain minus caudate. The [125I]RTI-55 binding to the DA transporter was further resolved into two components, termed sites 1a and 1b, by using human and monkey (Macaca mulatta) caudate membranes but not the membranes prepared from rat caudate or COS cells that transiently expressed the cloned cocaine-sensitive DA transporter complementary DNA. Similar experiments also resolved two components of the caudate 5-HT transporter. Viewed collectively, these data provide evidence that [125I]RTI-55 labels multiple binding sites associated with the DA and 5- HT transporters.

Volume 270, Issue 1, pp. 296-309, 07/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. J. Eshleman, K. Wolfrum, D. C. Mash, K. Christensen, and A. Janowsky Drug Interactions with the Dopamine Transporter in Cryopreserved Human Caudate J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 442 - 449. [Abstract] [Full Text]

				M. H. Baumann, R. B. Rothman, J. P. Pablo, and D. C. Mash In Vivo Neurobiological Effects of Ibogaine and Its O-Desmethyl Metabolite, 12-Hydroxyibogamine (Noribogaine), in Rats J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 531 - 539. [Abstract] [Full Text]

				R. Tao, Z. Ma, and S. B. Auerbach Differential Effect of Local Infusion of Serotonin Reuptake Inhibitors in the Raphe versus Forebrain and the Role of Depolarization-Induced Release in Increased Extracellular Serotonin J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 571 - 579. [Abstract] [Full Text]

				S. R. Letchworth, H. R. Smith, L. J. Porrino, B. A. Bennett, H. M. L. Davies, T. Sexton, and S. R. Childers Characterization of a Tropane Radioligand, [3H]2beta -Propanoyl-3beta -(4-tolyl) Tropane ([3H]PTT), for Dopamine Transport Sites in Rat Brain J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 686 - 696. [Abstract] [Full Text]

				S. Chalon, L. Garreau, P. Emond, L. Zimmer, M.-P. Vilar, J.-C. Besnard, and D. Guilloteau Pharmacological Characterization of (E)-N-(3-iodoprop-2-enyl)-2beta -Carbomethoxy-3beta -(4'-methylphenyl)nortropane as a Selective and Potent Inhibitor of the Neuronal Dopamine Transporter J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 648 - 654. [Abstract] [Full Text]

				R. B. Rothman, M. A. Ayestas, C. M. Dersch, and M. H. Baumann Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates : Implications for Primary Pulmonary Hypertension Circulation, August 24, 1999; 100(8): 869 - 875. [Abstract] [Full Text] [PDF]

				A. J. Eshleman, M. Carmolli, M. Cumbay, C. R. Martens, K. A. Neve, and A. Janowsky Characteristics of Drug Interactions with Recombinant Biogenic Amine Transporters Expressed in the Same Cell Type J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 877 - 885. [Abstract] [Full Text]

				C. Xu and M. E. A. Reith WIN 35,428 and Mazindol Are Mutually Exclusive in Binding to the Cloned Human Dopamine Transporter J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 920 - 927. [Abstract] [Full Text]

				S. R. Tella, B. Ladenheim, and J. L. Cadet Differential Regulation of Dopamine Transporter after Chronic Self-administration of Bupropion and Nomifensine J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 508 - 513. [Abstract] [Full Text]

				S. R. Tella, B. Ladenheim, A. M. Andrews, S. R. Goldberg, and J. L. Cadet Differential Reinforcing Effects of Cocaine and GBR-12909: Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Dopaminergic System J. Neurosci., December 1, 1996; 16(23): 7416 - 7427. [Abstract] [Full Text] [PDF]

				S. G. F. Rasmussen, F. I. Carroll, M. J. Maresch, A. D. Jensen, C. G. Tate, and U. Gether Biophysical Characterization of the Cocaine Binding Pocket in the Serotonin Transporter Using a Fluorescent Cocaine Analogue as a Molecular Reporter J. Biol. Chem., February 9, 2001; 276(7): 4717 - 4723. [Abstract] [Full Text] [PDF]